Manufacturing and product quality is key to CRT’s success.

To bring the vast potential of cell therapy to the broadest possible patient population, CRT is focused on developing products that can be manufactured to the highest possible quality standards, but with processes and at a scale that ensure affordability of new treatments.

CRT builds on decades of proprietary technology and practical know-how to manufacture large and scalable volumes of quality, consistent products, with a single umbilical cord having potential to produce billions of doses of finished product.

CRT is working with a strong network of global manufacturing, quality and supply chain experts committed to delivering the next generation of cell therapy.

Corlicyte^® and Corlisome^® are developed in facilities operating under GMP standards of quality and regulatory compliance.